The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature

Background: The human anti-IL-6 receptor antibody tocilizumab (TCZ) has been approved for the treatment of rheumatoid arthritis (RA) and giant cell arteritis (GCA). It is observed that CRP levels drop quickly after starting TCZ treatment. This may lead to misinterpretation of laboratory results when...

全面介绍

书目详细资料

Principais autores:	Mark Berman, Ronen Ben-Ami, Shlomo Berliner, Marina Anouk, Ilana Kaufman, Adi Broyde, Sara Borok, Ori Elkayam
格式:	Artigo
语言:	Inglês
出版:	MDPI AG 2021-03-01
丛编:	Life
主题:	tocilizumab infection rheumatoid arthritis giant cell arteritis C-reactive protein inflammation
在线阅读:	https://www.mdpi.com/2075-1729/11/3/258
标签:	添加标签 没有标签, 成为第一个标记此记录!